GSK Ties Up With Arrowhead to Develop NASH Drug Candidate

Arrowhead Pharmaceuticals Inc on Monday entered a drug development deal with GlaxoSmithKline Plc under which the British drugmaker will develop and market Arrowhead’s potential treatment for patients with fatty liver disease NASH. Read More